SynthesisBMC pregnancy and childbirth2026
Comparison of pregnancy outcomes and physical conditions of infants in patients with gestational diabetes mellitus treated with metformin and insulin: a meta-analysis study.
Synthesis in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGestational diabetes mellitus (GDM) is a common complication during pregnancy, which seriously affects the health of mothers and infants. Metformin and insulin are both commonly used therapeutic drugs, but the effects of the two on pregnancy outcomes and the physical condition of the infants remain undetermined. This study conducted a meta-analysis to compare the effects of two drugs in the treatment of gestational diabetes mellitus (GDM), providing a basis for clinical medication.
methodsOur research systematically searched the PubMed, Embase, and Cochrane Library databases to include randomized controlled trials (RCTS) of metformin and insulin in the treatment of GDM. The search period was up to March 2025. Literature screening, data extraction and quality evaluation were independently completed by two researchers, and statistical analysis was performed using RevMan 5.4 software.
resultsEventually, 8 RCTS were included, involving a total of 2,350 patients with GDM. Meta-analysis showed that the cesarean section rate in the metformin group was 26.3%, which was lower than 33.7% in the insulin group (RR = 0.78, 95%CI:0.75–0.81, P < 0.05). The incidence of gestational hypertension in the metformin group was 13.8% (26 out of 188 patients), which was lower than 18.6% (34 out of 183 patients) in the insulin group (RR = 0.74, 95% CI: 0.69–0.79, P < 0.05). The cesarean section rate was 30.9% (58/188) in the metformin group vs. 38.8% (71/183) in the insulin group (RR = 0.78, 95% CI:0.75–0.81, P < 0.05). Neonatal hypoglycemia occurred in 5.9% (11/188) of the metformin group vs. 9.8% (18/183) of the insulin group (RR = 0.60, 95% CI:0.57–0.63, P < 0.05). Macrosomia rates were 14.9% (28/188) vs. 19.7% (36/183) in the two groups, respectively (RR = 0.78, 95% CI:0.73–0.83, P < 0.05).
conclusionCompared with insulin, metformin in the treatment of gestational diabetes mellitus can reduce the rate of cesarean section, the incidence of gestational hypertension, the incidence of neonatal hypoglycemia and the incidence of macrosomia, and can be an effective treatment option for patients with GDM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.